6955 Stock Overview
Bonraybio Co., Ltd., a development stage company, manufactures medical instruments and solutions for the male infertility market.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Bonraybio Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | NT$158.00 |
52 Week High | NT$167.50 |
52 Week Low | NT$77.00 |
Beta | 0 |
1 Month Change | 8.97% |
3 Month Change | 66.32% |
1 Year Change | n/a |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | 82.87% |
Recent News & Updates
Recent updates
Shareholder Returns
6955 | TW Biotechs | TW Market | |
---|---|---|---|
7D | -1.3% | 1.6% | 0.2% |
1Y | n/a | -22.0% | 28.8% |
Return vs Industry: Insufficient data to determine how 6955 performed against the TW Biotechs industry.
Return vs Market: Insufficient data to determine how 6955 performed against the TW Market.
Price Volatility
6955 volatility | |
---|---|
6955 Average Weekly Movement | 8.1% |
Biotechs Industry Average Movement | 5.1% |
Market Average Movement | 4.9% |
10% most volatile stocks in TW Market | 8.7% |
10% least volatile stocks in TW Market | 2.3% |
Stable Share Price: 6955's share price has been volatile over the past 3 months.
Volatility Over Time: 6955's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of TW stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2015 | n/a | n/a | bonraybio.com |
Bonraybio Co., Ltd., a development stage company, manufactures medical instruments and solutions for the male infertility market. The company provides LensHooke X12 PRO semen analysis systems; and LensHooke X1 PRO semen quality analyzers. It also offers consumables, such as CS3 semen test slides; CA0/CA1 sperm separation solutions; and CS1 semen test cassettes.
Bonraybio Co., Ltd. Fundamentals Summary
6955 fundamental statistics | |
---|---|
Market cap | NT$2.70b |
Earnings (TTM) | NT$0 |
Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs 6955 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
6955 income statement (TTM) | |
---|---|
Revenue | NT$0 |
Cost of Revenue | NT$0 |
Gross Profit | NT$0 |
Other Expenses | NT$0 |
Earnings | NT$0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did 6955 perform over the long term?
See historical performance and comparison